SEARCH

SEARCH BY CITATION

FilenameFormatSizeDescription
cei12358-sup-0001-ts1-2,fs1-2.doc159K

Fig. S1. Investigator's global assessment of laryngeal patients treated in the controlled and open-label extension (OLE) phase of For Angioedema Subcutaneous Treatment (FAST-1).

Fig. S2. Patient-assessed symptom score in laryngeal patients during the open-label extension (OLE) phase of For Angioedema Subcutaneous Treatment (FAST-1).

Table S1. Investigator's global assessment of cutaneous patients treated in the open-label extension (OLE) phase of For Angioedema Subcutaneous Treatment (FAST-1).

Table S2. Investigator's global assessment of abdominal patients treated in the open-label extension (OLE) phase of For Angioedema Subcutaneous Treatment (FAST-1).

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.